Nephros (NEPH) Cash from Financing Activities (2010 - 2026)
Nephros (NEPH) posted Cash from Financing Activities of -$2000.0 for Q2 2026, down 100.69% on a QoQ basis from $289000.0 in Q1 2026, and down 100.0% year-over-year from -$inf billion in Q2 2025.
Powered by 
Analysis
Nephros (NEPH) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Nephros has reported Cash from Financing Activities for 17 years, with the latest figure at -$2000.0 in Q2 2026.
- On a quarterly basis, Cash from Financing Activities fell 100.0% year-over-year to -$2000.0 in Q2 2026; TTM through Jun 2026 was $284000.0, a 9566.67% increase from a year earlier, with the FY2025 full-year figure at -$5000.0, changed 0.0% from the prior year.
- Cash from Financing Activities was -$2000.0 for Q2 2026 at Nephros, down from $289000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $289000.0 in Q1 2026, with the low at -$111000.0 in Q4 2022.
- Average Cash from Financing Activities over 5 years is $14500.0, with a median of -$2000.0 recorded in 2023.
- The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities sank 250.0% in 2022, then soared 29000.0% in 2026.
- Over 5 years, Cash from Financing Activities stood at -$111000.0 in 2022, then surged by 97.3% to -$3000.0 in 2023, then surged by 66.67% to -$1000.0 in 2024, then changed by 0.0% to -$1000.0 in 2025, then sank by 100.0% to -$2000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$2000.0 (Q2 2026), $289000.0 (Q1 2026), and -$1000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 178.01 Bn | 172.41 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Intuitive Surgical | 131.29 Bn | 126.08 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Medtronic | 116.38 Bn | 107.56 Bn | 6.34 Bn | -343.00 Mn |
| 4 | Stryker | 106.01 Bn | 102.53 Bn | 4.50 Bn | -95.00 Mn |
| 5 | Boston Scientific | 63.40 Bn | 62.86 Bn | 3.85 Bn | -410.00 Mn |
| 6 | Edwards Lifesciences | 48.89 Bn | 44.64 Bn | 1.35 Bn | -300,000.00 |
| 7 | Alcon | 32.59 Bn | 31.13 Bn | 1.68 Bn | -510.00 Mn |
| 8 | Dexcom | 31.84 Bn | 29.89 Bn | 830.00 Mn | -607.30 Mn |
| 9 | Steris | 20.61 Bn | 20.13 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Nephros | 48.31 Mn | 43.62 Mn | 4.03 Mn | -2,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,000.00 |
| Mar 31, 2026 | 289,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Dec 31, 2023 | -3,000.00 |
| Jun 30, 2023 | -2,000.00 |
| Mar 31, 2023 | -74,000.00 |
| Dec 31, 2022 | -111,000.00 |
| Sep 30, 2022 | -69,000.00 |
| Jun 30, 2022 | -67,000.00 |
| Mar 31, 2022 | 281,000.00 |
| Dec 31, 2021 | -37,000.00 |
| Sep 30, 2021 | 46,000.00 |
| Jun 30, 2021 | 231,000.00 |
| Mar 31, 2021 | -3,000.00 |